Long-term study of a weight-loss drug for trial graduates
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests a drug called Maridebart Cafraglutide for long-term weight management in people who completed a previous related trial. It looks at how well the drug works and its safety over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the main MARITIME-1 trial and its week 72 visit.
- You must not have stopped the study drug during the main trial.
- You must be able to start this extension within 7 days of your week 72 visit.
- You must not have a body mass index (BMI) lower than 18.5.
- You must use approved birth control during treatment and for 16 weeks after your last dose.
- You must not be pregnant, breastfeeding, or planning to become pregnant during the study period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called maridebart cafraglutide for people with heart failure (where the heart doesn't pump as well as it should) and obesity. The goal is to see if it can help improve symptoms and outcomes.
This study tests an investigational medicine to help people who have lost weight keep it off. It's for adults without diabetes who haven't used similar weight-loss drugs before.
This study tests a new injectable medication (NNC0662-0419) designed to help people with obesity lose weight. Researchers are comparing different ways of increasing the dose to find the safest and most effective approach.
This study tests the long-term effects of a medication called maridebart cafraglutide for weight management. It is for people who already completed a 72-week study of this drug and want to continue treatment.
This study tests a new weekly injection (maridebart cafraglutide) to see if it helps lower the risk of heart problems in people with heart disease and overweight. It is for adults who have had a heart attack, stroke, or artery blockages and also have a BMI of 27 or higher.
This study is testing whether a new medicine, called Maridebart Cafraglutide, can help people with obstructive sleep apnea who are already using a CPAP machine. The medicine may help with weight loss and potentially improve sleep apnea. Participants will either receive the medicine or a placebo (an inactive substance), and the study lasts for several months.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.